Yazılar

Pfizer Sees Stable Vaccine Policy Under Trump Despite RFK Jr. Appointment

/in /tarafından

Pfizer does not anticipate major changes to U.S. vaccine policies under the Trump administration in 2025, even though President-elect Donald Trump has nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Department of Health and Human Services (HHS).

Speaking at an investor conference, Pfizer CEO Albert Bourla confirmed he had met with both Trump and RFK Jr. over dinner and described their relationship as positive. “If he’s confirmed, we will work with him to advance the right policies,” Bourla said.

Kennedy has long been criticized for questioning the safety and efficacy of vaccines, which have been instrumental in combating disease worldwide. While he rejects the “anti-vaccine” label, Kennedy has indicated that he would not block access to vaccines. Trump, meanwhile, has suggested that he may end certain childhood vaccination programs if concerns about safety arise.

Bourla highlighted Trump’s commitment to reforming the role of pharmacy benefit managers (PBMs), middlemen in the U.S. healthcare system who negotiate drug prices. Trump announced plans to eliminate PBMs, which Bourla argued could significantly lower patient out-of-pocket costs for medications.

Vaccine Market Outlook

Pfizer, which produces vaccines for COVID-19, pneumococcal disease, and RSV (respiratory syncytial virus), has faced market pressure since Trump’s announcement of Kennedy as his HHS nominee. However, Bourla reassured investors that Pfizer expects 2025 sales for its COVID-19 vaccine and treatment to remain consistent with 2024 levels.

Financial Performance and Turnaround Strategy

Pfizer’s financial outlook provided some relief to investors amid ongoing concerns over its future performance. The company forecasts 2025 adjusted profit between $2.80 and $3.00 per share, in line with analysts’ average estimate of $2.88. It also projects revenue between $61 billion and $64 billion, slightly below Wall Street’s consensus of $63.26 billion.

Shares rose 3.7% to $26.20 following the forecast, though Pfizer’s stock has dropped nearly 12% this year and remains well below its pandemic-era peak. The pharmaceutical giant has faced investor criticism, most notably from hedge fund Starboard Value, over its acquisition strategy and the lack of profitable drugs resulting from recent deals and internal research efforts.

In response, Bourla defended Pfizer’s strategy, which includes aggressive cost-cutting measures and the sale of non-core businesses to reduce debt. The company is under increasing pressure to introduce new blockbuster drugs to offset revenue declines from top sellers set to lose patent protection.

Conclusion

Despite concerns surrounding Trump’s choice of RFK Jr. for HHS and broader investor criticism, Pfizer remains cautiously optimistic about vaccine policies and its financial performance in 2025. The company continues to focus on cost efficiency, innovation, and policy collaboration to stabilize its outlook in a challenging post-pandemic environment.

 

Healthcare Stocks Drop Amid Push for Legislative Changes to Business Models

/in /tarafından

Shares of major healthcare companies, including UnitedHealth Group, Cigna, and CVS Health, dropped by up to 5% on Wednesday as concerns mounted over new legislation and public backlash that could disrupt their business operations. These companies, which are key players in the private health insurance sector and pharmaceutical supply chain, also face increasing pressure from lawmakers and patients to change their business practices.

The decline in stock prices follows the introduction of bipartisan legislation aimed at breaking up pharmacy benefit managers (PBMs), which are companies that act as intermediaries between insurers, pharmacies, and drug manufacturers. The legislation, first reported by The Wall Street Journal, targets the growing scrutiny PBMs have faced for inflating drug prices to boost profits, a practice that has drawn the attention of both Congress and the Federal Trade Commission (FTC).

Shares of UnitedHealth Group, Cigna, and CVS Health, which also own pharmacy businesses, all closed down at least 5% following the news. This stock movement comes at a time when insurance companies are already under public scrutiny, particularly after the tragic shooting of Brian Thompson, the CEO of UnitedHealth Group’s insurance arm, last week, which had already caused a dip in healthcare stocks.

The new Senate bill, backed by Senators Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.), proposes that companies owning both health insurers and PBMs divest their pharmacy operations within three years. According to The Wall Street Journal, a companion bill is also expected to be introduced in the House.

Warren criticized PBMs for driving up drug costs and harming small pharmacies. “My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen,” she said, emphasizing the negative impact PBMs have on both patients and independent pharmacies.

The largest PBMs in the U.S., including Optum Rx (UnitedHealth), Caremark (CVS), and Express Scripts (Cigna), collectively manage around 80% of the country’s prescriptions, according to the FTC. These companies play a central role in negotiating drug prices and administering insurance formularies, creating potential conflicts of interest when they also own pharmacies.